Sodium zirconium cyclosilicate compared with potassium restriction for hyperkalemia management in type 2 diabetes: The SILVERSTAR trial.
Masahide Hamaguchi, Junya Hironaka, Hiroshi Okada et al.
✦ AI-curated · Sources linked
In 30 seconds
The SILVERSTAR trial evaluated the noninferiority of sodium zirconium cyclosilicate versus a potassium-restricted diet for managing hyperkalemia in individuals with type 2 diabetes. In a multicenter, open-label, randomized controlled trial, normokalemia was achieved in 77.8% of the sodium zirconium group compared to 68.4% in the diet group, failing to demonstrate noninferiority. The mean serum potassium was lower in the sodium zirconium group by 0.23 mEq/L.
Key findings
- Normokalemia was achieved in 77.8% of the sodium zirconium group versus 68.4% in the diet group.
- The risk difference for achieving normokalemia was +9.4 percentage points.
- In the per-protocol analysis, normokalemia occurred in 83.9% of the sodium zirconium group.
- Mean serum potassium levels were lower by 0.23 mEq/L in the sodium zirconium group.
Why it matters
Understanding the effectiveness of sodium zirconium cyclosilicate compared to dietary management for hyperkalemia is crucial for optimizing treatment strategies in patients with type 2 diabetes, particularly in those at risk for elevated potassium levels.